Hormone receptor status was available in approximately 70% (7,053) of total breast cancer cases, out of which 50% were double hormone receptor positive tumors (ER+ PR+), followed by 33% of single hormone receptor positive tumors (ER+ or PR+), whereas 17% were double negative tumors (ER- PR-). This evidence concerns the gene ESR1 and breast carcinoma.